Advances in the treatment of chronic myeloid leukemia.
Advances in the treatment of chronic myeloid leukemia.
复制标题
DOI：
10.1186/1741-7015-9-99
复制
发表时间：
2011-08-26
期刊：
影响因子：
9.3
通讯作者：
Deininger MW
中科院分区：
文献类型：
--
作者：
Eiring AM;Khorashad JS;Morley K;Deininger MW
尽管伊马替尼作为一种有效的治疗新诊断的慢性髓性白血病（CML）的方法已经被确立，但该领域仍在几个方面取得进展。在这篇小型综述中，我们涵盖了新诊断患者中第二代酪氨酸激酶抑制剂的最新结果，调查了停止治疗的策略状态，并报告了新的小分子抑制剂来治疗耐药疾病，重点是靶向BCR-ABL的T315I突变体的药物。由于这些进展，一线治疗的标准治疗开始倾向于达沙替尼和尼罗替尼，尽管需要更多的观察来完全支持这一点。完全停止治疗仍然是临床试验的问题，必须更多地了解白血病细胞在治疗后持续存在的机制。然而，对于T315I突变的患者来说，有一个好消息，因为有效的药物如ponatinib正在获得监管部门的批准。尽管有这些有希望的数据，加速期或胚期疾病仍然是一个挑战，可能是由于bcr - abl不依赖的耐药。
Although imatinib is firmly established as an effective therapy for newly diagnosed patients with chronic myeloid leukemia (CML), the field continues to advance on several fronts. In this minireview we cover recent results of second generation tyrosine kinase inhibitors in newly diagnosed patients, investigate the state of strategies to discontinue therapy and report on new small molecule inhibitors to tackle resistant disease, focusing on agents that target the T315I mutant of BCR-ABL. As a result of these advances, standard of care in frontline therapy has started to gravitate toward dasatinib and nilotinib, although more observation is needed to fully support this. Stopping therapy altogether remains a matter of clinical trials, and more must be learned about the mechanisms underlying the persistence of leukemic cells with treatment. However, there is good news for patients with the T315I mutation, as effective drugs such as ponatinib are on their way to regulatory approval. Despite these promising data, accelerated or blastic phase disease remains a challenge, possibly due to BCR-ABL-independent resistance.
登录
查看更多内容
影响因子：
158.5
作者：
Druker, Brian J.;Guilhot, Francois;Larson, Richard A.
通讯作者：
Larson, Richard A.
影响因子：
50.3
作者：
Chan WW;Wise SC;Kaufman MD;Ahn YM;Ensinger CL;Haack T;Hood MM;Jones J;Lord JW;Lu WP;Miller D;Patt WC;Smith BD;Petillo PA;Rutkoski TJ;Telikepalli H;Vogeti L;Yao T;Chun L;Clark R;Evangelista P;Gavrilescu LC;Lazarides K;Zaleskas VM;Stewart LJ;Van Etten RA;Flynn DL
通讯作者：
Flynn DL
影响因子：
158.5
作者：
Hughes, TP;Kaeda, J;Holmes, H
通讯作者：
Holmes, H
影响因子：
20.3
作者：
Mueller, Martin C.;Cortes, Jorge E.;Hochhaus, Andreas
通讯作者：
Hochhaus, Andreas
影响因子：
51.1
作者：
Mahon, Francois-Xavier;Rea, Delphine;Rousselot, Philippe
通讯作者：
Rousselot, Philippe